| Patient | Sarah Walker |
|---|---|
| Date of birth | 1976-12-23 |
| Identifiers | MRN HR-ET019-SYN; SSN (made up) 000-19-7062 |
| Document date | 2026-11-01 |
| Author | Harriet Okonjo-Bell, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Establishing care for high blood pressure found at a workplace screening, morning headaches and protein in the urine at last year's executive physical, in a company founder who travels most weeks. Concerns: She wants to keep building her company and keep traveling to her agents, and does not want to be told to slow down; She is worried that her kidneys could fail and wants to know plainly what the numbers mean; She wants a plan that works on the road: medicines, readings, food and tests. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Losartan 50 mg oral tablet, one tablet each morning | One tablet each morning, at the same home time when traveling | Oral route | 2026-02-23 to 2026-03-09 | completed | S |
| Losartan 100 mg oral tablet, one tablet each morning | One tablet each morning | Oral route | 2026-03-09 | active | S |
| Empagliflozin 10 mg oral tablet, one tablet each morning; stop on days of vomiting, diarrhea or not eating, and before surgery | One tablet each morning, with sick-day rules | Oral route | 2026-02-23 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-02-23 | active | S |
| Ondansetron 4 mg orally disintegrating tablet, one tablet on the tongue every 8 hours as needed for nausea, for up to two days | Every 8 hours as needed for nausea, up to two days | Oral route | 2026-04-13 to 2026-04-15 | completed | S |
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-04-27 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Twelve-lead electrocardiogram | 2026-02-09 to 2026-02-09 | completed | S |
| 24-hour ambulatory blood pressure monitoring on a day at home, with readings every 20 minutes by day and every 30 minutes by night | 2026-02-10 to 2026-02-11 | completed | S |
| Ultrasound of both kidneys and the bladder | 2026-02-23 to 2026-02-23 | completed | S |
| Transthoracic echocardiogram | 2026-03-09 to 2026-03-09 | completed | S |
| Advance care planning conversation, about 20 minutes | 2026-06-08 to 2026-06-08 | completed | S |
| Screening mammogram, both breasts | 2026-06-22 to 2026-06-22 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-02-09 | Influenza vaccine, inactivated, this season | completed | S |
| 2026-06-08 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2026-06-08 | Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) | completed | S |
| 2026-06-08 | Hepatitis B vaccine (HepB-CpG), dose 1 of 2 | completed | S |
| 2026-08-17 | Hepatitis B vaccine (HepB-CpG), dose 2 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1904 | Hair loss and scalp disease in her thirties, while working as a laundress; resolved | D (CLM-0003) |
| 1916 | High blood pressure, for which she took a rest cure at Hot Springs, Arkansas, the year before this visit; no treatment recorded | D (CLM-0006) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| mother | Died when she was a young child; cause not recorded in the cited source | D (CLM-0002) | |
| father | Died when she was a young child; cause not recorded in the cited source | D (CLM-0002) |
| Concern | Status | Evidence |
|---|---|---|
| She wants to keep building her company and keep traveling to her agents, and does not want to be told to slow down | active | S |
| She is worried that her kidneys could fail and wants to know plainly what the numbers mean | active | S |
| She wants a plan that works on the road: medicines, readings, food and tests | active | S |
Most recent measures: Sodium [Moles/volume] in Serum or Plasma 140 on 2026-08-17; Potassium [Moles/volume] in Serum or Plasma 4.8 on 2026-08-17; Carbon dioxide, total [Moles/volume] in Serum or Plasma 25 on 2026-08-17; Creatinine [Mass/volume] in Serum or Plasma 1.3 on 2026-08-17; Glucose [Mass/volume] in Serum or Plasma 88 on 2026-04-13; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 50 on 2026-08-17; Albumin/Creatinine [Mass Ratio] in Urine 128 on 2026-08-17; Hemoglobin A1c/Hemoglobin.total in Blood 5.4 on 2026-02-09; Cholesterol [Mass/volume] in Serum or Plasma 172 on 2026-04-27; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 98 on 2026-04-27; Cholesterol in HDL [Mass/volume] in Serum or Plasma 48 on 2026-04-27; Triglyceride [Mass/volume] in Serum or Plasma 130 on 2026-04-27; Hemoglobin [Mass/volume] in Blood 12.6 on 2026-08-17; Thyrotropin [Units/volume] in Serum or Plasma 1.9 on 2026-02-09; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-08-17; Calcium [Mass/volume] in Serum or Plasma 9.4 on 2026-02-23; Phosphate [Mass/volume] in Serum or Plasma 3.6 on 2026-02-23; Parathyrin.intact [Mass/volume] in Serum or Plasma 58 on 2026-02-23; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 31 on 2026-02-23; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 on 2026-04-27; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-06-08; Total score [AUDIT-C] 1 on 2026-06-08 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Elevated blood pressure at intake (166/102 mmHg, average of two readings), first found at a workplace screening; ambulatory monitoring to confirm | resolved | confirmed | R03.0 | S — Synthetic presenting finding, superseded by the confirmed diagnosis at two weeks. |
| Albumin in the urine (urine albumin-to-creatinine ratio 286 mg/g) with eGFR 54 by the race-free CKD-EPI 2021 equation; she recalls protein in the urine at an executive physical a year ago, and those records are requested; to be repeated and investigated | resolved | confirmed | R80.9 | S — Synthetic presenting finding, superseded by the kidney diagnosis at two weeks. |
| Hypertension, stage 2, confirmed by 24-hour ambulatory monitoring (24-hour mean 149/94, daytime 154/98, night 140/88 without the normal nighttime fall), with left ventricular hypertrophy on ECG and mild hypertensive retinopathy; synthetic modern episode linked to her documented high blood pressure | active | confirmed | I12.9 | S — Synthetic modern diagnosis anchored to the documented hypertension and nephritis. |
| Chronic kidney disease G3a A2 (eGFR 54 to 55 mL/min/1.73 m2 by the race-free CKD-EPI 2021 equation; albumin-to-creatinine ratio 286 to 294 mg/g; present for more than three months), most likely hypertensive kidney disease; bland urine sediment and normal-sized kidneys on ultrasound; 5-year kidney failure risk 1.6% | active | confirmed | N18.31 | S — Synthetic kidney findings anchored to the documented nephritis and death from kidney disease. |
| Hyperlipidemia: LDL 174 mg/dL; 10-year ASCVD risk 7.9% by the Pooled Cohort Equations (intermediate) | active | confirmed | E78.5 | S — Synthetic laboratory finding. |
| Viral gastroenteritis after a sales convention, with mild volume depletion and losartan and empagliflozin held under her sick-day rules; no acute kidney injury; resolved | resolved | confirmed | A08.4 | S — Synthetic intercurrent illness; not a historical claim. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-02-09 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-02-09 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-02-09 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 25 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-02-09 | Creatinine [Mass/volume] in Serum or Plasma | 1.22 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 2026-02-09 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-02-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 54 | mL/min/{1.73_m2} | 60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3a | Low | S |
| 2026-02-09 | Albumin/Creatinine [Mass Ratio] in Urine | 286 | mg/g | Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3) | High | S |
| 2026-02-09 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.4 | % | Below 5.7% is normal | Normal | S |
| 2026-02-09 | Cholesterol [Mass/volume] in Serum or Plasma | 250 | mg/dL | <=199 mg/dL | High | S |
| 2026-02-09 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 174 | mg/dL | Below 130 mg/dL; lower on treatment by at least 30% | High | S |
| 2026-02-09 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 46 | mg/dL | >=50 mg/dL | Low | S |
| 2026-02-09 | Triglyceride [Mass/volume] in Serum or Plasma | 150 | mg/dL | <=149 mg/dL | High | S |
| 2026-02-09 | Hemoglobin [Mass/volume] in Blood | 12.4 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-02-09 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.4-4.5 mIU/L | Normal | S |
| 2026-02-09 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-02-23 | Albumin/Creatinine [Mass Ratio] in Urine | 294 | mg/g | Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3) | High | S |
| 2026-02-23 | Creatinine [Mass/volume] in Serum or Plasma | 1.21 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 2026-02-23 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 55 | mL/min/{1.73_m2} | 60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3a | Low | S |
| 2026-02-23 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-02-23 | Phosphate [Mass/volume] in Serum or Plasma | 3.6 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 2026-02-23 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 58 | pg/mL | 15-65 pg/mL | Normal | S |
| 2026-02-23 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 31 | ng/mL | 30-100 ng/mL | Normal | S |
| 2026-03-09 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-09 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-09 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 24 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-03-09 | Creatinine [Mass/volume] in Serum or Plasma | 1.29 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 2026-03-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 51 | mL/min/{1.73_m2} | 60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3a | Low | S |
| 2026-04-13 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-04-13 | Potassium [Moles/volume] in Serum or Plasma | 4.9 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-13 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 21 | mmol/L | 22-29 mmol/L | Low | S |
| 2026-04-13 | Creatinine [Mass/volume] in Serum or Plasma | 1.46 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 2026-04-13 | Glucose [Mass/volume] in Serum or Plasma | 88 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-04-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 44 | mL/min/{1.73_m2} | 60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3a | Low | S |
| 2026-04-27 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-04-27 | Potassium [Moles/volume] in Serum or Plasma | 4.7 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-27 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 24 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-04-27 | Creatinine [Mass/volume] in Serum or Plasma | 1.31 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 2026-04-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 50 | mL/min/{1.73_m2} | 60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3a | Low | S |
| 2026-04-27 | Albumin/Creatinine [Mass Ratio] in Urine | 176 | mg/g | Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3) | High | S |
| 2026-04-27 | Cholesterol [Mass/volume] in Serum or Plasma | 172 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-04-27 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 98 | mg/dL | Below 130 mg/dL; lower on treatment by at least 30% | Normal | S |
| 2026-04-27 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 48 | mg/dL | >=50 mg/dL | Low | S |
| 2026-04-27 | Triglyceride [Mass/volume] in Serum or Plasma | 130 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-04-27 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-35 U/L | Normal | S |
| 2026-08-17 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-08-17 | Potassium [Moles/volume] in Serum or Plasma | 4.8 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-08-17 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 25 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-08-17 | Creatinine [Mass/volume] in Serum or Plasma | 1.3 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 2026-08-17 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 50 | mL/min/{1.73_m2} | 60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3a | Low | S |
| 2026-08-17 | Albumin/Creatinine [Mass Ratio] in Urine | 128 | mg/g | Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3) | High | S |
| 2026-08-17 | Hemoglobin [Mass/volume] in Blood | 12.6 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-08-17 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-06-08 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-06-08 | Total score [AUDIT-C] | 1 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-02-09 | Body height | 163 | cm | S |
| 2026-02-09 | Body weight | 79 | kg | S |
| 2026-02-09 | Body mass index (BMI) [Ratio] | 29.7 | kg/m2 | S |
| 2026-02-09 | Systolic blood pressure | 166 | mm[Hg] | S |
| 2026-02-09 | Diastolic blood pressure | 102 | mm[Hg] | S |
| 2026-02-09 | Heart rate | 82 | /min | S |
| 2026-02-09 | Respiratory rate | 16 | /min | S |
| 2026-02-09 | Body temperature | 36.7 | Cel | S |
| 2026-02-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-02-23 | Body height | 163 | cm | S |
| 2026-02-23 | Body weight | 78.6 | kg | S |
| 2026-02-23 | Body mass index (BMI) [Ratio] | 29.6 | kg/m2 | S |
| 2026-02-23 | Systolic blood pressure | 160 | mm[Hg] | S |
| 2026-02-23 | Diastolic blood pressure | 100 | mm[Hg] | S |
| 2026-02-23 | Heart rate | 80 | /min | S |
| 2026-02-23 | Respiratory rate | 16 | /min | S |
| 2026-02-23 | Body temperature | 36.6 | Cel | S |
| 2026-02-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-03-09 | Body height | 163 | cm | S |
| 2026-03-09 | Body weight | 78.2 | kg | S |
| 2026-03-09 | Body mass index (BMI) [Ratio] | 29.4 | kg/m2 | S |
| 2026-03-09 | Systolic blood pressure | 148 | mm[Hg] | S |
| 2026-03-09 | Diastolic blood pressure | 92 | mm[Hg] | S |
| 2026-03-09 | Heart rate | 78 | /min | S |
| 2026-03-09 | Respiratory rate | 16 | /min | S |
| 2026-03-09 | Body temperature | 36.7 | Cel | S |
| 2026-03-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-04-27 | Body height | 163 | cm | S |
| 2026-04-27 | Body weight | 77.2 | kg | S |
| 2026-04-27 | Body mass index (BMI) [Ratio] | 29.1 | kg/m2 | S |
| 2026-04-27 | Systolic blood pressure | 136 | mm[Hg] | S |
| 2026-04-27 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 2026-04-27 | Heart rate | 76 | /min | S |
| 2026-04-27 | Respiratory rate | 16 | /min | S |
| 2026-04-27 | Body temperature | 36.6 | Cel | S |
| 2026-04-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-08-17 | Body height | 163 | cm | S |
| 2026-08-17 | Body weight | 75.8 | kg | S |
| 2026-08-17 | Body mass index (BMI) [Ratio] | 28.5 | kg/m2 | S |
| 2026-08-17 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-08-17 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-08-17 | Heart rate | 72 | /min | S |
| 2026-08-17 | Respiratory rate | 16 | /min | S |
| 2026-08-17 | Body temperature | 36.7 | Cel | S |
| 2026-08-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-04-13 | Body height | 163 | cm | S |
| 2026-04-13 | Body weight | 76.4 | kg | S |
| 2026-04-13 | Body mass index (BMI) [Ratio] | 28.8 | kg/m2 | S |
| 2026-04-13 | Systolic blood pressure | 112 | mm[Hg] | S |
| 2026-04-13 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-04-13 | Heart rate | 96 | /min | S |
| 2026-04-13 | Respiratory rate | 16 | /min | S |
| 2026-04-13 | Body temperature | 37.4 | Cel | S |
| 2026-04-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-06-08 | Body height | 163 | cm | S |
| 2026-06-08 | Body weight | 76.6 | kg | S |
| 2026-06-08 | Body mass index (BMI) [Ratio] | 28.8 | kg/m2 | S |
| 2026-06-08 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-06-08 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-06-08 | Heart rate | 74 | /min | S |
| 2026-06-08 | Respiratory rate | 16 | /min | S |
| 2026-06-08 | Body temperature | 36.7 | Cel | S |
| 2026-06-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-02-09 | Establishing care for high blood pressure found at a workplace screening, morning headaches and protein in the urine at last year's executive physical, in a company founder who travels most weeks | finished | S |
| 2026-02-23 | Two-week review of the 24-hour ambulatory blood pressure and the repeat kidney tests, with a kidney ultrasound and a nephrology consultation | finished | S |
| 2026-03-09 | Two-week check of potassium and creatinine after starting losartan and empagliflozin, home readings, and the echocardiogram | finished | S |
| 2026-04-27 | Eleven-week review: home readings on maximum losartan, urine albumin, kidney function after a recent gastroenteritis, lipids on atorvastatin | finished | S |
| 2026-08-17 | Six-month review: blood pressure at goal, urine albumin, kidney function, hemoglobin, mood, and the travel season ahead | finished | S |
| 2026-04-13 | Same-day sick visit for viral gastroenteritis with sick-day rules | finished | S |
| 2026-06-08 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Nephrology consultation at the two-week visit for albuminuria and a reduced eGFR found at 49: the likely cause, whether more tests or a biopsy are needed, kidney-protective treatment, APOL1 testing, and monitoring that fits her travel | completed | GL-KDIGO-CKD-2024, GL-CMID-2026 | S |
| Confirm the diagnosis outside the office: 24-hour ambulatory monitoring on a day at home, and a validated upper-arm home monitor with a correctly sized cuff that travels with her, two readings morning and evening for seven days, travel days included; recheck in two weeks | completed | GL-AHA-HTN-2025, GL-CMID-2026 | S |
| Kidney evaluation: repeat urine albumin and creatinine at two weeks, compared with last year's results to establish chronicity; urinalysis; kidney ultrasound; calcium, phosphate, parathyroid hormone and 25-hydroxyvitamin D at baseline; every eGFR reported by the race-free CKD-EPI 2021 equation; no ibuprofen or naproxen | completed | GL-KDIGO-CKD-2024, GL-NKF-ASN-2021, GL-CKDEPI-2021, GL-CMID-2026 | S |
| Heart and vascular risk: ECG at intake and an echocardiogram for the left ventricular hypertrophy it shows; a fundus examination; TSH and A1c at diagnosis; lipid panel and 10-year ASCVD risk by the Pooled Cohort Equations | completed | GL-AHA-HTN-2025, GL-ACC-CHOL-2018, GL-CMID-2026 | S |
| Food: sodium under 2 g a day built on what she eats, not a new diet: a salt-free seasoning blend for the dishes she cooks on Sundays, smoked turkey in small amounts in place of salt pork, ordering strategies for banquets and restaurants, water instead of a third coffee on travel days; video sessions with a registered dietitian between trips; no potassium-based salt substitutes until her kidney tests and any new medicines are settled | completed | GL-AHA-HTN-2025, GL-KDIGO-CKD-2024 | S |
| Work and rest on her terms: she sets her schedule; the risks of uncontrolled blood pressure and kidney disease are stated plainly and any medicines are chosen to do the work, timed to her home clock across time zones, with a written sick-day card for her bag; a protected sleep window on travel nights and walking during layovers; video visits between trips and laboratory checks on her days at home | completed | GL-AHA-HTN-2025, GL-KDIGO-CKD-2024 | S |
| Mood and stress: PHQ-9 at intake and yearly | completed | GL-USPSTF-DEP-2023, GL-CMID-2026 | S |
| Vaccines: influenza today; pneumococcal, hepatitis B and Tdap needs reviewed at the preventive visit; influenza and COVID-19 each autumn | completed | GL-CDC-IMZ-2026 | S |
| Gastroenteritis: oral rehydration, ondansetron as needed, losartan and empagliflozin held until she has eaten and drunk normally for 24 hours, then restarted; a metabolic panel within a week | completed | GL-KDIGO-CKD-2024 | S |
| As the nephrologist advised: losartan 50 mg, increased to 100 mg at two weeks if potassium and creatinine allow; empagliflozin 10 mg daily; sick-day rules for both; potassium and creatinine two to four weeks after each start or increase, accepting a creatinine rise of up to 30%; urine albumin at about three months, then every six months; blood pressure goal below 130/80, lower toward a systolic of 120 if well tolerated, with amlodipine as the next medicine | completed | GL-KDIGO-CKD-2024, GL-KDIGO-BP-2021, GL-AHA-HTN-2025, GL-CMID-2026 | S |
| Atorvastatin 20 mg daily, chosen with her after reviewing her 10-year ASCVD risk of 7.9% with CKD as a risk enhancer; lipid panel and ALT at four to twelve weeks | completed | GL-ACC-CHOL-2018, GL-KDIGO-CKD-2024, GL-CMID-2026 | S |
| Amlodipine 5 mg added for home readings above goal on losartan 100 mg; every laboratory check booked on a home day before her trips are scheduled, by her office, after two missed checks | completed | GL-AHA-HTN-2025, GL-KDIGO-CKD-2024, GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Blood pressure below 130/80 mmHg in the clinic and at home within six months, lower toward a systolic of 120 if well tolerated | 2026-08-17 | completed | 122/76 in the clinic; home average 123/77 on losartan 100 mg and amlodipine 5 mg | S |
| Urine albumin-to-creatinine ratio lower by at least 30% within six months | 2026-08-17 | completed | 286 to 294 mg/g at baseline; 128 mg/g at six months, 56% lower | S |
| Kidney function stable, without a fall in eGFR of more than 30% after starting treatment | 2026-08-17 | completed | eGFR 54 to 55 at baseline; 50 to 51 on treatment, a dip of under 10% | S |
| Sodium under 2 g a day using foods she likes, at home and on the road | 2026-08-17 | active | Salt-free seasoning at home and ordering strategies on the road; restaurant meals still the hardest part | S |
| LDL cholesterol lower by at least 30% | 2026-04-27 | completed | 174 to 98 mg/dL on atorvastatin 20 mg, 44% lower | S |
| Care that fits her work: every check scheduled around her travel, by her choice | 2026-08-17 | completed | Laboratory checks booked before trips are planned after two missed checks; video visits between trips | S |